Epizyme stock: buy or sell?

EPZM stock price: $10.34 -1.24% At close on October 18th, 2019

Updated on:
October 18th, 2019


Epizyme shares declined -1.24% to $10.34 on Oct/18.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.

Should I buy Epizyme stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Epizyme stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Epizyme stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 6 ratings published for EPZM stock in the last month.

The general sentiment of these ratings is bullish for EPZM stock, with 6 positive ratings.
Is EPZM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-24HC Wainwrightn/aBuy
2019-1-7Leerink SwannMarket PerformOutperform

Epizyme stock analysis

Daily outlook

Shares of Epizyme declined a lame -1.24% and closed at $10.34.

Epizyme shares declined -1.24% to $10.34 on Oct 18th. Since price and SMA200d lines crossed down on September/19, EPZM fell $-1.40 per share (-11.93%).

EPZM stock chart (daily)

Weekly outlook

After sliding a hair-raising -8.47% in a week last week, Epizyme closed this week at $10.34 and escalated a pretty good 3.09%. Late September EPZM rocketed an extraordinary 6.53% in just one week.

Since mid September, when EPZM stock price broke down the 40-weeks moving avarage line, it slid $-1.62 per share (-13.55%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since SMA20w and SMA40w crossed up early April, EPZM price slid a -24.19%.

EPZM stock chart (weekly)

Epizyme stock price history

Epizyme stock went public on May 31st, 2013 with a price of $20.001. Since then, EPZM stock declined a -48.30%, with a yearly average of -8.10%.

1: Adjusted price after possible price splits or reverse-splits.

Epizyme stock historical price chart

EPZM stock reached 52-week highs on June at $16.59, and all-time highs 2013-07-17 with a price of 45.72.

Epizyme stock price target is $20.50

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 4 price targets for EPZM stock:
EPZM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-24HC WainwrightSet Price Targetn/a$25.00-
2019-2-27OppenheimerLowers Target$27.00$18.00-33.3%
(in average)$27.00$20.50-24.0%
The price target for Epizyme stock is $20.50, moving in a range between $25.00 and $18.00. In average, analysts' outlook on EPZM price forecast is negative, downgrading the prediction by a -24.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Epizyme missed the expectations of the analysts and reported a bloodcurdling EPS of $-0.29 per share when experts were expecting $-0.49.
EPZM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw an amazing increase of 117.00% to $21.70 million dollars. In line, its earnings margin (compared to sales) rocketed to -569.72%, that is $-123.63 million.

EPZM annual Sales and Income evolution
2013$68 M-$-3.48 M-5.1%-
2014$41 M-39.53%$-55.01 M-132.8%1,480.60%
2015$2.56 M-93.82%$-132.38 M-5170.9%140.66%
2016$8.01 M212.77%$-110.21 M-1376.4%-16.74%
2017$10 M24.89%$-134.31 M-1343.1%21.86%
2018$22 M117.00%$-123.63 M-569.7%-7.95%

Quarterly financial results

Epizyme reported $9.70 million in sales for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter income marked $-22.95 million with a profit margin of -236.55%. Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an outstanding growth and skyrocketed a inf%.
EPZM quarterly Sales and Income evolution
2017-Q2$10 M-$-28.02 M-280.2%-
2018-Q2$12 M20.00%$-29.13 M-242.7%3.95%
2018-Q4$10 M-19.17%$-22.95 M-236.5%-21.23%

Epizyme ownership

When you are planning to invest in a company, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.

Bearish positions for EPZM stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related companies:

Market cap$941.4 M$146.5 B$73.0 B$13.5 M$105.9 B
Total shares91.0 M1,770.0 M708.7 M16.7 M2,490.0 M
Float shares70.5 M1,750.0 M706.3 M13.9 M2,450.0 M
  - Institutional holdings (%)93.2%76.5%77.6%8.1%11.0%
  - Insider holdings (%)4.9%0.7%0.2%16.9%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Epizyme summary

Friday, October 18th, 2019
Day range$10.29 - $10.55
Previous close$10.47
Session gain-1.24%
Average true range$0.48
50d mov avg$11.72
100d mov avg$12.44
200d mov avg$12.15
Daily patternlt03a
Weekly pattern lb06a

Epizyme performance

To better understand Epizyme performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Epizyme to , Celgene, Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics:
DAREDare Bioscience1.25%-19.80%-14.74%
SGENSeattle Genetics16.42%26.34%21.73%

Epizyme competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Epizyme. We picked 6 companies as Epizyme competitors as they are in the same industry or have similar market objectives.